Lv11
66 积分 2024-08-05 加入
POS0803 VUNAKIZUMAB IN ACTIVE ANKYLOSING SPONDYLITIS: A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, SEAMLESS, PHASE 2/3 STUDY
7天前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
16天前
已完结
Current therapeutic strategies in the management of diabetic foot ulcers
17天前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
21天前
已完结
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines
22天前
已完结
Recent advances in therapeutic cancer vaccines
22天前
已完结
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
3个月前
已完结
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea
6个月前
已完结
A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy
8个月前
已完结
皖公网安备34019202002308
